Inclusion Criteria:

- Patients with nasopharyngeal carcinoma in stage IVa or Ivb and patients with
metastatic hepatocellular carcinoma were planned for tumor biopsy or primary surgeon

- Age 18 to 70 years.

- Willing to sign a durable power of attorney

- Able to understand and sign the Informed Consent Document

- Life expectancy of greater than three months

- Patients of both genders must be willing to practice birth control from the time of
enrollment on this study and for up to four months after receiving the preparative
regimen.

- Serology:

- Seronegative for HIV antibody.

- Women of child-bearing potential must have a negative pregnancy test because of
the potentially dangerous effects of the preparative chemotherapy on the fetus.

- Hematology:

- WBC (> 3000/mm(3)).

- Platelet count greater than 100,000/mm.

- Hemoglobin greater than 8.0 g/dl.

- Chemistry:

- Serum ALT/AST less or equal to 2.5 times the upper limit of normal.

- Serum creatinine less than or equal to 1.6 mg/dl.

- Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

Exclusion Criteria:

- Previous treatment with IL-12.

- Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

- Active systemic infections, coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.

- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).

- Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).

- Concurrent systemic steroid therapy.